4.7 Article

Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome

Journal

BRAIN
Volume 145, Issue 10, Pages 3383-3390

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/awac223

Keywords

endocannabinoid; episodic ataxia; paroxysmal tonic upgaze; nystagmus; developmental delay

Funding

  1. Rady Children's Institute for Genomic Medicine (RCIGM)
  2. Clinical and Translational Science Award [5 UL1 TR002550]
  3. NIH-NINDS [K23NS119666]
  4. NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director [U01HG007672]
  5. Canadian Institute of Health Research [377869, 426534]
  6. Fonds de Recherche du Quebec Sante (FRQS)
  7. Canadian Institutes of Health Research (CIHR)
  8. FRQS
  9. Canadian Institutes for Health Research [426534, 201610PJT377869]
  10. CIHR
  11. Compute Canada
  12. Fondation du Grand defi Pierre Lavoie
  13. Healthy Brains for Healthy Lives (HBHL)
  14. NCATS [UL1TR002550]
  15. Shaffer Family Foundation
  16. Anne and Henry Zarrow Foundation

Ask authors/readers for more resources

Mutation of the endocannabinoid gene DAGLA causes a pediatric syndrome characterized by developmental delay, ataxia, and abnormal head and eye movements. The truncated protein may be mislocalized, leading to the observed phenotype. This study highlights the first direct link between an endocannabinoid system component and human genetic disease.
Bainbridge et al. show that mutation of the endocannabinoid gene DAGLA causes a paediatric syndrome with developmental delay, ataxia and abnormal head and eye movements. DAGLA activity is preserved in affected individuals, suggesting that mislocalization of the truncated protein may account for the observed phenotype. The endocannabinoid system is a highly conserved and ubiquitous signalling pathway with broad-ranging effects. Despite critical pathway functions, gene variants have not previously been conclusively linked to human disease. We identified nine children from eight families with heterozygous, de novo truncating variants in the last exon of DAGLA with a neuro-ocular phenotype characterized by developmental delay, ataxia and complex oculomotor abnormality. All children displayed paroxysms of nystagmus or eye deviation accompanied by compensatory head posture and worsened incoordination most frequently after waking. RNA sequencing showed clear expression of the truncated transcript and no differences were found between mutant and wild-type DAGLA activity. Immunofluorescence staining of patient-derived fibroblasts and HEK cells expressing the mutant protein showed distinct perinuclear aggregation not detected in control samples. This report establishes truncating variants in the last DAGLA exon as the cause of a unique paediatric syndrome. Because enzymatic activity was preserved, the observed mislocalization of the truncated protein may account for the observed phenotype. Potential mechanisms include DAGLA haploinsufficiency at the plasma membrane or dominant negative effect. To our knowledge, this is the first report directly linking an endocannabinoid system component with human genetic disease and sets the stage for potential future therapeutic avenues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available